Evidence map›Paper›PMID 40903280›Full record

ArticleExperimental animals2026

Early-stage therapeutic efficacy of TNAP inhibition using a novel milder murine model of CKD-MBD.

Kaori Soma, José Luis Millán, Anthony Pinkerton, Masanori Izumi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental animals, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kaori SomaDaiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.
José Luis MillánSanford Burnham Prebys, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA.
Anthony PinkertonBoundless Bio, 10955 Alexandria Way, Suite 100, San Diego, CA 92121, USA.
Masanori IzumiDaiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) is a complicated systemic disease displaying various pathophysiological symptoms including mineral bone disorder (CKD-MBD). Ideally, early intervention for CKD-MBD would be desirable, however, there is not enough evidence regarding treatment of CKD-MBD, especially in its early stages, due to its multifactorial pathophysiology and the difficulty in generating adequate animal models. In this study, we evaluated the efficacy of a tissue nonspecific alkaline phosphatase (TNAP) inhibitor, SBI-425 in a CKD-MBD animal model, produced by a combination of nephrectomy and high inorganic phosphate (P

Indexed as

Alkaline PhosphataseChronic Kidney Disease-Mineral and Bone DisorderDisease Models, AnimalRenal Insufficiency, ChronicAnimalsBlood Urea NitrogenFibroblast Growth Factor-23Fibroblast Growth FactorsMaleMiceMice, Inbred C57BLNephrectomyParathyroid HormonePhosphatesAlkaline PhosphataseFgf23 protein, mouseFibroblast Growth Factor-23Fibroblast Growth FactorsParathyroid HormonePhosphatesanimal modelschronic kidney disease and mineral bone disorder (CKD-MBD)ectopic calcificationtherapeuticstissue nonspecific alkaline phosphatase (TNAP) inhibitor

Identifiers

PMID40903280
PMCPMC12826570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.